This site is intended for healthcare professionals.

SGLT inhibitors for treating type 1 diabetes: NICE technology appraisals TA597 and TA622

SGLT inhibitors for treating type 1 diabetes: NICE technology appraisals TA597 and TA622

Share
Share on facebook
Share on twitter
Share on linkedin
Share on email
12 June 2020
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Dr David Millar-Jones summarises the key points for primary care relating to use of sodium–glucose cotransporter inhibitors in people with type 1 diabetes.

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

Stay up to date...

Subscribe to our weekly email update with our  latest videos.

Before you go...

Would you like to subscribe to our weekly email update containing links to the latest videos on GPnotebook TV?

Subscribe to our weekly updates.

We also uses anonymous cookies to generate usage statistics. Please click here to find out more.